News
PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.
Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.
XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.
UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results